Published in Clin Neuropharmacol on October 01, 1996
Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans. Br J Clin Pharmacol (2001) 1.28
Steady-state pharmacokinetics and pharmacodynamics of CHF3381, a novel antineuropathic pain agent, in healthy subjects. Br J Clin Pharmacol (2005) 0.75
ESPEN Guidelines on Enteral Nutrition: Non-surgical oncology. Clin Nutr (2006) 2.89
A stellar relic from the early Milky Way. Nature (2002) 2.56
Two novel protein-tyrosine kinases, each with a second phosphotransferase-related catalytic domain, define a new class of protein kinase. Mol Cell Biol (1991) 2.47
Mutation position and type of substitution in the beta-subunit of the RNA polymerase influence in-vitro activity of rifamycins in rifampicin-resistant Mycobacterium tuberculosis. J Antimicrob Chemother (1995) 2.22
Identification of a novel SNF2/SWI2 protein family member, SRCAP, which interacts with CREB-binding protein. J Biol Chem (1999) 1.97
Selective induction by nerve growth factor of tyrosine hydroxylase and dopamine- -hydroxylase in the rat superior cervical ganglia. Proc Natl Acad Sci U S A (1971) 1.96
Effects of dexmedetomidine, a selective alpha 2-adrenoceptor agonist, on hemodynamic control mechanisms. Clin Pharmacol Ther (1989) 1.73
Search for supersymmetry using final states with one lepton, jets, and missing transverse momentum with the ATLAS detector in √s=7 TeV pp collisions. Phys Rev Lett (2011) 1.60
Hypokalaemia and other non-bronchial effects of inhaled fenoterol and salbutamol: a placebo-controlled dose-response study in healthy volunteers. Br J Clin Pharmacol (1987) 1.57
Expression of two novel eph-related receptor protein tyrosine kinases in mammary gland development and carcinogenesis. Oncogene (1994) 1.51
In vivo enhancement of tyrosine hydroxylation in rat striatum by tetrahydrobiopterin. Nature (1974) 1.51
Prospective randomized trial comparing the outcome and cost of in vitro fertilization with that of a traditional treatment algorithm as first-line therapy for couples with infertility. Fertil Steril (1999) 1.45
Comparative studies on the effect of the nerve growth factor on sympathetic ganglia and adrenal medulla in newborn rats. Brain Res (1972) 1.44
Observation of a centrality-dependent dijet asymmetry in lead-lead collisions at sqrt[S(NN)] =2.76 TeV with the ATLAS detector at the LHC. Phys Rev Lett (2010) 1.41
Pharmacokinetics of intravenous cefetamet (Ro 15-8074) and oral cefetamet pivoxil (Ro 15-8075) in young and elderly subjects. Antimicrob Agents Chemother (1989) 1.41
PDPH in obstetric anesthesia: comparison of 24-gauge Sprotte and 25-gauge Quincke needles and effect of subarachnoid administration of fentanyl. Reg Anesth (1993) 1.39
Measurement of dijet azimuthal decorrelations in pp collisions at sqrt(s)=7 TeV. Phys Rev Lett (2011) 1.39
Determination of the strange-quark density of the proton from ATLAS measurements of the W→ℓν and Z→ℓℓ cross sections. Phys Rev Lett (2012) 1.34
Search for new particles in two-jet final states in 7 TeV proton-proton collisions with the ATLAS detector at the LHC. Phys Rev Lett (2010) 1.32
Synthesis and biochemical evaluation of N-(4-phenylthiazol-2-yl)benzenesulfonamides as high-affinity inhibitors of kynurenine 3-hydroxylase. J Med Chem (1997) 1.31
Quantitative enzyme radioautography with 3H-Ro 41-1049 and 3H-Ro 19-6327 in vitro: localization and abundance of MAO-A and MAO-B in rat CNS, peripheral organs, and human brain. J Neurosci (1992) 1.30
Adherence to colposcopy among women with HIV infection. J Acquir Immune Defic Syndr (1999) 1.29
Functional analysis of an olfactory receptor in Drosophila melanogaster. Proc Natl Acad Sci U S A (2001) 1.28
Observation of associated near-side and away-side long-range correlations in sqrt[s(NN)]=5.02 TeV proton-lead collisions with the ATLAS detector. Phys Rev Lett (2013) 1.27
The effect of food on the pharmacokinetics of ofloxacin. Curr Med Res Opin (1986) 1.27
Improved methods for venous access: the Port-A-Cath, a totally implanted catheter system. J Clin Oncol (1986) 1.24
A meta-analytic investigation of linkage and association of common leptin receptor (LEPR) polymorphisms with body mass index and waist circumference. Int J Obes Relat Metab Disord (2002) 1.21
Association of a leucine(7)-to-proline(7) polymorphism in the signal peptide of neuropeptide Y with high serum cholesterol and LDL cholesterol levels. Nat Med (1998) 1.20
Search for dark matter candidates and large extra dimensions in events with a photon and missing transverse momentum in pp collision data at sqrt[s]=7 TeV with the ATLAS detector. Phys Rev Lett (2013) 1.19
Insulin production rate following glucose ingestion estimated by splanchnic C-peptide output in normal man. Diabetologia (1979) 1.19
Association between the functional variant of the catechol-O-methyltransferase (COMT) gene and type 1 alcoholism. Mol Psychiatry (1999) 1.15
Serum leptin concentrations in women with polycystic ovary syndrome. J Clin Endocrinol Metab (1997) 1.14
Search for a supersymmetric partner to the top quark in final states with jets and missing transverse momentum at sqrt[s] = 7 TeV with the ATLAS detector. Phys Rev Lett (2012) 1.13
Frequent blood-brain barrier disruption in the human cerebral cortex. Cell Mol Neurobiol (2001) 1.10
Inhibition by etomoxir of carnitine palmitoyltransferase I reduces hepatic glucose production and plasma lipids in non-insulin-dependent diabetes mellitus. Metabolism (1991) 1.10
Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa. Br J Clin Pharmacol (1995) 1.09
Search for tb resonances in proton-proton collisions at √s=7 TeV with the ATLAS detector. Phys Rev Lett (2012) 1.07
Sensitivity distribution and spatial summation within receptive-field center of retinal on-center ganglion cells and transfer function of the retina. J Neurophysiol (1970) 1.07
Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humans. Clin Pharmacol Ther (1995) 1.06
Rapid and sensitive single-step radiochemical assay for catechol-O-methyltransferase. J Neurochem (1982) 1.06
Search for a light Higgs boson decaying to long-lived weakly interacting particles in proton-proton collisions at sqrt[s] = 7 TeV with the ATLAS detector. Phys Rev Lett (2012) 1.05
An insertion/deletion polymorphism in the alpha2B-adrenergic receptor gene is a novel genetic risk factor for acute coronary events. J Am Coll Cardiol (2001) 1.04
The first adult case with 4-hydroxybutyric aciduria. J Inherit Metab Dis (1990) 1.04
The effect of a new specific alpha-amylase inhibitor on post-prandial glucose and insulin excursions in normal subjects and Type 2 (non-insulin-dependent) diabetic patients. Diabetologia (1984) 1.03
Automatic bone and plaque removal using dual energy CT for head and neck angiography: feasibility and initial performance evaluation. Eur J Radiol (2009) 1.02
Measurement of d sigma/dM and forward-backward charge asymmetry for high-mass Drell-Yan e(+)e(-) pairs from pp macro collisions at square root of s = 1.8 TeV. Phys Rev Lett (2001) 1.02
Effects of metformin treatment on glucose transporter proteins in subcellular fractions of skeletal muscle in (fa/fa) Zucker rats. Br J Pharmacol (1995) 1.02
Time course of the development of enzymes involved in the synthesis of norepinephrine in the superior cervical ganglion of the rat from birth to adult life. Brain Res (1972) 1.02
Inverse correlation between serum testosterone and leptin in men. J Clin Endocrinol Metab (1998) 1.01
Effects of timing of food and fluid volume on cefetamet pivoxil absorption in healthy normal volunteers. Antimicrob Agents Chemother (1990) 1.01
Nicotinamide is a brain constituent with benzodiazepine-like actions. Nature (1979) 1.00
Altered intracellular processing and release of neuropeptide Y due to leucine 7 to proline 7 polymorphism in the signal peptide of preproneuropeptide Y in humans. FASEB J (2001) 1.00
Some basic aspects of reversible inhibitors of monoamine oxidase-A. Acta Psychiatr Scand Suppl (1990) 1.00
Search for supersymmetry in events with three leptons and missing transverse momentum in √[s]=7 TeV pp collisions with the ATLAS detector. Phys Rev Lett (2012) 0.99
Leucine7 to proline7 polymorphism in the preproneuropeptide Y is associated with the progression of carotid atherosclerosis, blood pressure and serum lipids in Finnish men. Atherosclerosis (2001) 0.99
[Comparison of the new MAO-A inhibitors moclobemide, brofaromine and toloxatone with tranylcypromine in an animal experiment: significance for clinical practice]. Psychiatr Prax (1989) 0.98
On tyramine, food, beverages and the reversible MAO inhibitor moclobemide. J Neural Transm Suppl (1988) 0.97
Influence of antacid and ranitidine on the pharmacokinetics of oral cefetamet pivoxil. Antimicrob Agents Chemother (1990) 0.97
Pharmacokinetics of cefetamet pivoxil (Ro 15-8075) with ascending oral doses in normal healthy volunteers. Antimicrob Agents Chemother (1989) 0.96
Identification of new sequence variants in the leptin gene. J Clin Endocrinol Metab (1998) 0.96
Ro 19-6327, a reversible and highly selective monoamine, oxidase B inhibitor: a novel tool to explore the MAO-B function in humans. Adv Neurol (1990) 0.96
Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. J Pharmacol Exp Ther (1989) 0.95
Identification of a three-amino acid deletion in the alpha2B-adrenergic receptor that is associated with reduced basal metabolic rate in obese subjects. J Clin Endocrinol Metab (1999) 0.95
Renal hemodynamics and pharmacokinetics of bosentan with and without cyclosporine A. Kidney Int (2000) 0.95
Dose linearity and other pharmacokinetics of ofloxacin: a new, broad-spectrum antimicrobial agent. Pharmatherapeutica (1985) 0.95
Measurement of the strong coupling constant from inclusive jet production at the Tevatron pp collider. Phys Rev Lett (2002) 0.94
Association between the functional polymorphism of catechol-O-methyltransferase gene and alcohol consumption among social drinkers. Alcohol Clin Exp Res (2000) 0.94
Influence of maturation and growth on cefetamet pivoxil pharmacokinetics: rational dosing for infants. Antimicrob Agents Chemother (1996) 0.94
From moclobemide to Ro 19-6327 and Ro 41-1049: the development of a new class of reversible, selective MAO-A and MAO-B inhibitors. J Neural Transm Suppl (1990) 0.94
Search for gluinos and scalar quarks in pp collisions at square root[s] = 1.8 TeV using the missing energy plus multijets signature. Phys Rev Lett (2002) 0.93
[Controlled randomized double-blind study for the comparison of the treatment of patients with essential hypertension with homeopathic and with pharmacologically effective drugs]. Wien Klin Wochenschr (1982) 0.93
Measurement of human cerebral monoamine oxidase type B (MAO-B) activity with positron emission tomography (PET): a dose ranging study with the reversible inhibitor Ro 19-6327. Eur J Clin Pharmacol (1991) 0.93
Pooling analysis of genetic data: the association of leptin receptor (LEPR) polymorphisms with variables related to human adiposity. Genetics (2001) 0.93
Multiple-dose clinical pharmacology of the catechol-O-methyl-transferase inhibitor tolcapone in elderly subjects. Eur J Clin Pharmacol (1996) 0.92
Characterization of a novel murine testis-specific serine/threonine kinase. Gene (1994) 0.92
Severe hyperglycemia: effects of rehydration on endocrine derangements and blood glucose concentration. Diabetes (1979) 0.92
Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly. Clin Pharmacol Ther (1997) 0.92
Leucine 7 to proline 7 polymorphism in the neuropeptide y gene is associated with retinopathy in type 2 diabetes. Exp Clin Endocrinol Diabetes (2000) 0.92
Oral glucose tolerance test: effect of different glucose loads on splanchnic carbohydrate and substrate metabolism in healthy man. Metabolism (1980) 0.92
Local anesthetic myotoxicity: a case and review. Anesthesiology (1994) 0.92
Bioavailability of L-dopa after Madopar HBS administration in healthy volunteers. Eur Neurol (1987) 0.92
Nerve growth factor and preganglionic cholinergic nerves; their relative importance to the development of the terminal adrenergic neuron. Brain Res (1972) 0.91
Feedback inhibition by biosynthetic human insulin of insulin release in healthy human subjects. Am J Physiol (1982) 0.91
Receptor-operated calcium-permeable channels in vascular smooth muscle. J Cardiovasc Pharmacol (1989) 0.91
Acute effects of nimodipine on the cerebral blood flow and intracranial pressure. Neurochirurgia (Stuttg) (1985) 0.91
Alcoholic beverages produced by alcoholic fermentation but not by distillation are powerful stimulants of gastric acid secretion in humans. Gut (1997) 0.90
Hepatic metabolism and distribution of mifepristone and its metabolites in rats. Hum Reprod (1994) 0.90
Molecular characterization of the murine syk protein tyrosine kinase cDNA, transcripts and protein. Biochem Biophys Res Commun (1995) 0.90
Disposition kinetics of moclobemide, a monoamine oxidase-A enzyme inhibitor: single and multiple dosing in normal subjects. Clin Pharmacol Ther (1987) 0.90
Sedative and cardiovascular effects of medetomidine, a novel selective alpha 2-adrenoceptor agonist, in healthy volunteers. Br J Clin Pharmacol (1987) 0.90
Determination of midazolam and its alpha-hydroxy metabolite in human plasma and urine by high-performance liquid chromatography. Ther Drug Monit (1993) 0.89
The pharmacology of Parkinson's disease: basic aspects and recent advances. Experientia (1984) 0.89
Pharmacodynamics of lazabemide, a reversible and selective inhibitor of monoamine oxidase B. Br J Clin Pharmacol (1994) 0.89
Pharmacokinetics of oral cefetamet pivoxil (Ro 15-8075) and intravenous cefetamet (Ro 15-8074) in humans: a review. Curr Med Res Opin (1989) 0.88
Comparative effects of verapamil, tiapamil, diltiazem and nifedipine on systemic and splanchnic hemodynamics in man. Int J Clin Pharmacol Ther Toxicol (1987) 0.88
A population pharmacokinetic screen to identify demographic-clinical covariates of basiliximab in liver transplantation. Clin Pharmacol Ther (2001) 0.88
(E)-2(R)-[1(S)-(Hydroxycarbamoyl)-4-phenyl-3-butenyl]-2'-isobutyl-2'-(methanesulfonyl)-4-methylvalerohydrazide (Ro 32-7315), a selective and orally active inhibitor of tumor necrosis factor-alpha convertase. J Pharmacol Exp Ther (2002) 0.88
Cefetamet pivoxil: a review of its microbiology, toxicology, pharmacokinetics and clinical efficacy. Int J Antimicrob Agents (1992) 0.88
Clinical pharmacology of moclobemide during chronic administration of high doses to healthy subjects. Psychopharmacology (Berl) (1998) 0.87